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Dysregulation of proinflammatory versus
anti-inflammatory human TH17 cell functionalities
in the autoinflammatory Schnitzler syndrome
Rebecca Noster,a Heleen D. de Koning, MD, PhD,c,d Elisabeth Maier, PhD,b Martina Prelog, MD,e Elke Lainka, MD,f and
Christina E. Zielinski, MDa,b Berlin, Munich, Wuerzberg, and Essen, Germany, and Nijmegen, The Netherlands
GRAPHICAL ABSTRACT
Background: TH17 cells have so far been considered to be
crucial mediators of autoimmune inflammation. Two distinct
types of TH17 cells have been described recently, which differed
in their polarization requirement for IL-1b and in their
cytokine repertoire. Whether these distinct TH17 phenotypes
translate into distinct TH17 cell functions with implications for
human health or disease has not been addressed yet.
Objective: We hypothesized the existence of proinflammatory
and anti-inflammatory human TH17 cell functions based on the
differential expression of IL-10, which is regulated by IL-1b.
Considering the crucial role of IL-1b in the pathogenesis of
autoinflammatory syndromes, we hypothesized that IL-1b
mediates the loss of anti-inflammatory TH17 cell functionalities in
patients with Schnitzler syndrome, an autoinflammatory disease.
Methods: To assess proinflammatory versus anti-inflammatory
TH17 cell functions, we performed suppression assays and tested the
effects of IL-1b dependent and independent TH17 subsets on
modulating proinflammatory cytokine secretion by monocytes.
Patients with Schnitzler syndrome were analyzed for changes in
TH17 cell functions before and during therapy with IL-1b–blocking
drugs.
Results: Both TH17 cell subsets differ in their ability to suppress
T-cell proliferation and their ability tomodulate proinflammatory
cytokine production by antigen-presenting cells because of their
differential IL-10 expression properties. In patients with
Schnitzler syndrome, systemic overproduction of IL-1b translates
into aprofound loss of anti-inflammatoryTH17cell functionalities,
which can be reversed by anti–IL-1b treatment.
Conclusion: IL-1b signaling determines the differential
expression pattern of IL-10, which is necessary and sufficient to
induce proinflammatory versus anti-inflammatory TH17 cell
functions. Our data introduce TH17 cell subsets as novel players
in autoinflammation and thus novel therapeutic targets in
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autoinflammatory syndromes including other IL-1b mediated
diseases. This demonstrates for the first time alterations in the
adaptive immune system in patients with autoinflammatory
syndromes. (J Allergy Clin Immunol 2016;138:1161-9.)
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TH17 cells have been recognized as critical players in the path-
ogenesis of autoimmune diseases and in the clearance of extracel-
lular pathogens and fungi.1,2 In mice terminal differentiation of
TH17 cells is dependent on IL-23, which abrogates the induction
of IL-10 and promotes IFN-g coexpression in IL-17–producing
T helper cells. This confers pathogenicity to TH17 cells, as
evidenced most strikingly in the EAE mouse model of multiple
sclerosis.3 In human subjects 2 types of stable TH17 cells have
recently been identified in vivo.4 They differ in their property to
coexpress either IL-10 or IFN-g and in their microbial antigen
specificities. These distinct phenotypes are generated with
differential requirements for IL-1b during the polarization phase.
In humans IL-1b, but not IL-23, strongly suppresses IL-10 and
promotes IFN-g/T-bet induction.4
Despite this differential cytokine coexpression pattern, it has not
been demonstrated so far whether these distinct human TH17 cell
phenotypes indeed translate into different functionalities. Although
both subsets continue to express proinflammatory IL-17, the ques-
tion of whether anti-inflammatory IL-10 might confer a dominant
immunosuppressive functionality on TH17 cells is warranted. This
would necessitate a rethinking about the general concept of
TH17cells beingmajormediatorsof inflammatory tissuedestruction.
Autoinflammatory syndromes are characterized by overpro-
duction of IL-1b caused by mutations in the inflammasome, a
large intracellular multiprotein complex that leads to
maturation of IL-1b and IL-18.5 Due to the absence of inflamma-
some expression in cells of the adaptive immune system,
autoinflammation has been considered to be caused solely by
abrogations in innate immunity, although this could potentially
also translate into downstream alterations of adaptive immune
functions. Schnitzler syndrome belongs to this group of very
rare autoinflammatory syndromes. It presents with a chronic
urticarial rash, intermittent fever, arthralgia or arthritis, hepato-
megaly and/or splenomegaly, lymphadenopathy, leukocytosis,
and an increased erythrocyte sedimentation rate.6,7 We recently
demonstrated 2 variant cases with somatic mosaicism of
NLRP3 mutations in the myeloid lineage, leading to spontaneous
IL-1b secretion by PBMCs.8 Furthermore, increased IL-1b
secretion by LPS-stimulated PBMCs was reported.9 Hence, apart
from the monoclonal IgM gammopathy, the immunologic
significance of which is unknown, and IL-1b overproduction,
no immune-related abnormalities have been detected in patients
with Schnitzler syndrome so far.6
Because IL-1b is the critical switch factor that determines
whether TH17 cells can coexpress IL-10,
4 Schnitzler syndrome
represents an ‘‘experiment of nature’’ in which alterations in
adaptive immunity caused by systemic IL-1b overproduction can
be studied in vivo in human subjects. In addition, immunologic
perturbations, such as systemic in vivo inhibition of IL-1b by
targeted therapies with IL-1 receptor antagonist (IL-1Ra; anakinra)
and IL-1b–neutralizing antibodies (canakinumab and gevokizu-
mab), can be performed in vivo in this disease setting.
This revealed the existence of 2 functionally distinct subsets of
human TH17 cells, which can be categorized into proinflamma-
tory versus anti-inflammatory subsets because of the dominant
role of IL-10 and despite the heterogeneous cytokine repertoire
of both TH17 cell subsets. We also demonstrate a loss of
anti-inflammatory TH17 cells in patients with Schnitzler
syndrome, which could be restored to physiological levels upon
therapeutic IL-1b inhibition. This could have implications for
disease pathogenesis and future therapeutic strategies.
METHODS
Cell purification and sorting
CD141 monocytes and CD41 T cells were isolated from PBMCs after
density gradient sedimentation with Ficoll-Paque Plus (GE Healthcare,
Fairfield, Conn) by means of positive selection with CD14- or CD4-specific
microbeads, respectively (Miltenyi Biotec, Bergisch Gladbach, Germany).
T helper cell subsets were sorted to greater than 97% purity as follows:
TH1 subset, CCR6
2CCR42CXCR31CD45RA2CD252CD82; TH2 subset,
CCR62CCR41CXCR32CD45RA2CD252CD82; and TH17 subset, CCR6
1
CCR41CXCR32CD45RA2CD252CD82. The following antibodies were
used for fluorescence-activated cell sorting (FACS): phycoerythrin-
conjugated anti-CCR6 (11A9; BD Biosciences, San Jose, Calif), phycoery-
thrin-indotricarbocyanine–conjugated anti-CCR4 (1G1; BD Biosciences),
allophycocyanin-conjugated anti-CXCR3 (1C6/CXCR3; BD Biosciences),
phycoerythrin-Cy5–conjugated anti-CD45RA (HI100, BD Biosciences), R
phycoerythrin cyanin 5.1–conjugated anti-CD8 (B9.11; Coulter Immunotech,
Krefeld, Germany), and fluorescein isothiocyanate–conjugated anti-CD25
(B1.49.9; Immunotech). Naive T cells were isolated as CD45RA1
CD45RO2CCR71CD252CD82 to a purity of greater than 99% after staining
with the aforementioned antibodies against CD45RA, CD25, andCD8, as well
as fluorescein isothiocyanate–conjugated CD45RO (UCHL1; Immunotech)
and anti-CCR7 (150503; R&D Systems, Minneapolis, Minn), followed by
staining with biotinylated anti-IgG2a (1080-08; SouthernBiotech, Birming-
ham, Ala) and streptavidin–Pacific blue (Molecular Probes, Invitrogen,
Eugene, Ore). Permission for experiments with human primary cells was
obtained from the ethics committee of the Charite-Universit€atsmedizin Berlin
(EA1/221/11), the ethics committee of the University of Wuerzburg (protocol
no. 239/10), and the Radboud University Medical Center, Nijmegen, with
approval by the local medical ethics committee, as well as from the ethics
committee of the Technical University of Munich (195/15s). Samples from
patients with Schnitzler syndrome from the NCT0139035010 cohort were
obtained before and at different time points after treatment with canakinumab
during a proof-of-principle immunologic study at the Charite-Universit€atsme-
dizin Berlin. Patients were eligible for enrollment in the study if they had
active Schnitzler syndrome. All patients selected for this study responded to
treatment with complete remission, as defined by physician’s global assess-
ment on overall autoinflammatory disease activity. For more information on
clinical trial details, we refer to NCT01390350 and Krause et al.10
Samples from patients with Schnitzler syndrome after treatment with
gevokizumab were obtained from the Nijmegen Center for Immunodeficiency
and Autoinflammation. Clinical trial information is deposited in the EU
Clinical Trials Register (EudraCT no. 2013-002562-39). PBMCs of patients
with systemic juvenile idiopathic arthritis (Still disease) who were naive for
any biologic treatment were obtained from the Laboratory of Pediatric
Rheumatology and Special Immunology, University Children’s Hospital,
University of Wuerzburg and the German Registry for Autoinflammatory
Diseases (AID-Net).
Abbreviations used
FACS: Fluorescence-activated cell sorting
IL-1Ra: IL-1 receptor antagonist
Treg: Regulatory T
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Cell sorting was performed with a FACSAria III or MoFlo (Beckman
Coulter, Brea, Calif). Flow cytometry was performed with a CytoFLEX
(Beckman Coulter), FACSCanto (BD Biosciences), and MACSQuant
(Miltenyi Biotec). Flow cytometric data were analyzed with FlowJo software
(TreeStar, Ashland, Ore).
Cell culture
Cells were cultured in RPMI-1640 medium supplemented with 2 mmol/L
glutamine, 1% (vol/vol) nonessential amino acids, 1% (vol/vol) sodium
pyruvate, penicillin (50 U/mL), streptomycin (50 mg/mL; all from Invitrogen,
Carlsbad, Calif), and 5% (vol/vol) human serum (Charite Blood Center). T
cells were labeled with carboxyfluorescein succinimidyl ester (CFSE),
according to standard protocols. Monocytes were cultured for 24 hours with
or without LPS (100 ng/mL; Sigma-Aldrich, St Louis, Mo).
Suppression assays
Naive CD45RA1 CFSE-labeled CD41 T cells were cocultured as
responder T cells with equal or titrated numbers of different T helper cell sub-
sets in the presence of equal numbers of irradiated anti-CD3–coated (OKT3)
PBMCs (28 Gy) as feeder cells. In some experiments naive but also T helper
cell subsets were used as responder cells, where indicated. CFSE dilution was
analyzed on day 4 by FACS. For IL-10 neutralization, purified rat anti-human
IL-10 (clone JES3-19F1, isotype control rat IgG2a) was used at a concentration
of 10 mg/mL. For suppression assays with material from patients, we
cocultured the patients’ TH17 cells with healthy allogeneic naive T cells,
which allowed us to assess the suppressive properties of the patients’
TH17 cells, irrespective of any potential alterations in the patients’ naive
T-cell (responder cell) proliferation capacity.
Cytokine analyses
For intracellular cytokine staining, T cells were restimulated for 5 hours
with phorbol 12-myristate 13-acetate and ionomycin in the presence of
brefeldin A (all from Sigma-Aldrich) for the final 2.5 hours of culture.
Monocytes were stimulated for 40 hours with LPS (100 ng/mL, Sigma) in the
presence of brefeldin A and the absence of phorbol 12-myristate 13-acetate
and ionomycin. Cells were fixed andmade permeablewith Cytofix/Cytoperm,
according to the manufacturer’s instructions (BD Biosciences). Cells were
stained with phycoerythrin- or allophycocyanin-conjugated anti–IL-10 (both
JES3-19F1; BD Biosciences) and Alexa Fluor 647– or fluorescein isothiocy-
anate–conjugated anti–IL-17 (both eBIO64-DEC17; eBioscience, San Diego,
Calif), PE/Cy7-conjugated TNF-a (BioLegend, San Diego, Calif), and
phycoerythrin- or allophycocyanin-conjugated anti–GM-CSF (R&D
Systems). Flow cytometric data were analyzed with FlowJo software.
Cytokines in T-cell culture supernatants were measured by using ELISA
according to a standard protocol after restimulation of cultured T cells
(5 3 104 cells in 200 mL) with phorbol-12-13-dibutyrate (50 nmol/L,
Sigma-Aldrich) and plate-bound anti-CD3 (1 mg/mL, TR66) for 8 hours.
Data were analyzed by the Softmax program. IL-1b and TNF-a secretion
by monocytes was measured by using the cytometric bead array, according
to the manufacturer’s instructions (BD Biosciences), as well as by ELISA
(DuoSet ELISA Kits; R&D Systems).
Statistics
The Student t test was used to test the statistical significance of the results.
P values of .05 or less were considered statistically significant.
RESULTS
Human TH17 cells have IL-10–dependent
suppressive properties
TH17 cells have a heterogeneous cytokine profile that goes
beyond production of their lineage identifying cytokines IL-17
and IL-22.1 To investigate whether human TH17 cells have
anti-inflammatory properties, we performed T-cell suppression
assays, which are classical surrogate assays to demonstrate
regulatory activities of regulatory T (Treg) cells in both mice
and human subjects. TH17 cells from healthy control subjects
were sorted according to the differential expression of CCR6,
CXCR3, and CCR4, which we have previously shown to highly
enrich for the TH17 cell subset at the exclusion of TH1 and TH2
cells.4,11 To further exclude potentially contaminating Treg
cells, we performed negative sorting for CD25 expression.
Surprisingly, TH17 cells suppressed the proliferation of naive
responder T helper cells in a dose-dependent manner (Fig 1, A).
We next addressed the mechanism of TH17 cell–mediated
responder T-cell suppression. IL-10 is a classical anti-
inflammatory cytokine that can be produced by the
CCR61CXCR32CCR41 TH17 cell subset.
4 Compared with the
TH1 and TH2 cell subsets, TH17 cells have the highest IL-10
coexpression at the single-cell level after polyclonal stimulation
with plate-bound CD3 and CD28 mAbs (Fig 1, B and C).
For this reason, we analyzed whether IL-10 mediated the
suppression of responder T cells. Blocking IL-10 with neutral-
izing antibodies was indeed sufficient to reverse responder T-cell
suppression by TH17 cells to levels of responder cell proliferation
seen in the absence of suppressor cells (Fig 1, D). This demon-
strates that their ability to produce IL-10 provides TH17 cells
with net immunosuppressive functions. This was surprising
considering that they continue to produce proinflammatory
cytokines, such as GM-CSF, which has been reported to confer
pathogenic functions to TH17 cells in the EAE mouse model
12,13
and correlates with multiple sclerosis in human subjects (see Fig
E1 in this article’s Online Repository at www.jacionline.org).14
Therefore IL-10 exerts a dominant immunosuppressive
functionality on human TH17 cells despite coexpression of other
proinflammatory cytokines, such as IL-17 and GM-CSF.
We have also dissected the ability of TH17–IL-10
1 cells to
differentially suppress distinct T helper cell subsets in addition
to naive T helper cells. Our data demonstrate that TH17 cells
can suppress the proliferation of not only naive responder cells
but also effector T helper cell subsets of different lineages with
variable efficiency (see Fig E2 in this article’s Online Repository
at www.jacionline.org).
Together, these data demonstrate IL-10–dependent suppressive
properties of human TH17 cells in an in vitro suppression assay.
Activation increases regulatory properties of
human TH17 cells
Human TH17 cells have previously been demonstrated to upre-
gulate IL-10 expression upon T-cell receptor stimulation.4 To test
whether TH17 cell activation translates into more potent
suppressive properties, we preactivated human TH17 cells for
48 hours with CD3 and CD28 mAbs and assessed responder
T-cell suppression (Fig 2). For comparison of regulatory strengths,
we also performed suppression assays with professional
CD25highCD127low Treg cells, which expressed greater than
90% forkhead box protein 3 (see Fig E3 in this article’s Online
Repository at www.jacionline.org). In cultures with TH17 cells
that were not preactivated but only received weak activation
stimuli from allogeneic anti-CD3–coated feeder cells during the
coculture period, 29.6% 6 4.5% (mean 6 SEM) of responder
cells proliferated. This low stimulation strength was consistent
with low IL-10 expression levels by nonpreactivated TH17 cells
4
and correlated with low suppressive function (Fig 2, B).
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In cultures with Treg cells, only 3.2%6 1.0% (mean6 SEM)
of responder cells proliferated compared with 53% 6 5.2% in
the absence of suppressor cells. As expected, polyclonal preacti-
vation with plate-bound CD3 and CD28 antibodies induced IL-10
upregulation in TH17 cells (not preactivated, 2.0% 6 0.8%;
preactivated, 13.8% 6 2.4%). This correlated with an increase
in their suppressive function (responder cell proliferation,
2.7%6 0.6%). Interestingly, the suppressive strength of activated
IL-10–producing TH17 cells was even comparable with that of
Treg cells (no significant difference, P 5 .7; Fig 2), which are
specialized in immunosuppression by multiple mechanisms.15
Two types of human TH17 cells that differ in
regulatory properties
Human TH17 cell subsets with distinct antigen specificities and
differential priming requirements for IL-1b, which determines
either IL-10 or IFN-g coexpression patterns, have been described
recently.4 Whether this phenotypic diversity within the TH17 cell
subset translates into functional differences has not been analyzed
yet. We hypothesized that there are differential suppressive prop-
erties of IL-101 versus IL-102 TH17 cells. To test this,
CCR61CXCR32CCR41TH17 cells, which we had demonstrated
to coproduce IL-10,4 were restimulated with IL-1b for 48 hours.
This completely suppressed the ability of TH17 cells to express
IL-10, which is in accordance with published data (see Fig E4
in this article’s Online Repository at www.jacionline.org).4
IL-1b2treated and untreated TH17 cells, which differed in their
ability to coexpress IL-10, were then used for suppression assays.
In accordance with our hypothesis, we observed that both
TH17 cell subsets differed in their suppressive functions. With
IL-102 TH17 cells, responder cell proliferation amounted to
83.5% of the control responder T-cell proliferation in the absence
of suppressive T cells. This did not differ statistically from control
FIG 1. Human TH17 cells have IL-10–dependent regulatory functions. A, TH17 cells were isolated as
CXCR32CCR41CCR61CD252 T helper cells and cocultured at different ratios with naive CFSE-labeled
responder T cells in the presence of feeder cells for 3 days. Data are representative of 3 individual
experiments. B and C, Intracellular staining and flow cytometry of human T helper cell subsets on day 5 after
48 hours of stimulation with CD3 and CD28 mAbs. T helper cell subsets were isolated according to the
differential expression of CXCR3, CCR4, and CCR6, as indicated. Different symbols indicate individual
donors. D, The suppression assay was performed as in Fig 1, A, with equal numbers of responder and
TH17 cells with or without addition of anti–IL-10 (10 mg/mL).
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responder T-cell proliferation (P 5 .2), whereas with IL-101
TH17 cells, responder T-cell proliferation was strongly impaired
(>3-fold reduction, Fig 3). This demonstrated that IL-1b acts as
a critical switch factor for determining proinflammatory versus
anti-inflammatory functionalities of human TH17 cells.
Two types of TH17 cells that differ in their property
to modulate innate cytokine secretion
Suppression assays are considered powerful surrogates for
determining the regulatory properties of T cells in vitro. Even
though they have clearly demonstrated the suppressive properties
of Treg cells previously, it has been questioned whether in vivo
properties of T cells with regulatory functions are reflected by
this in vitro assay with high fidelity.16 To corroborate our
finding of differential regulatory properties of TH17–IL-10
1
and TH17–IL-10
2 cells, we also used another experimental
readout for regulatory functions. We therefore tested the
ability of both TH17 types to downregulate production of
proinflammatory cytokines, in particular IL-1b, by antigen-
presenting cells, such as monocytes. CD141 monocytes were
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stimulated with LPS, which is sufficient for induction of IL-1b
secretion in human subjects in accordance with published
data.17 They were cocultured with 48-hour preactivated TH1,
TH2, and TH17 cells, which were isolated according to their dif-
ferential expression of CXCR3, CCR4, and CCR6. TH17 cells
efficiently suppressed the secretion of bioactive IL-1b by mono-
cytes (Fig 4, A). Interestingly, the TH17 cell subset was the most
efficient T helper cell subset for innate IL-1b suppression
compared with the TH1 and TH2 cell subsets. This correlated
with its ability to produce the highest levels of IL-10 upon activa-
tion (Fig 4, B). This suppressive property was not only restricted
to IL-1b secretion. TH17 cells, but not TH1 and TH2 cells, also
significantly suppressed the secretion of other proinflammatory
cytokines, such as TNF-a, by monocytes in response to
LPS (see Fig E5, A, in this article’s Online Repository at
www.jacionline.org), although the frequency of TNF-a1
monocytes was not altered after coculture with different T helper
cell subsets (see Fig E5, B).
To test whether the 2 distinct TH17 cell subsets differed in their
ability to suppress proinflammatory cytokine secretion by
monocytes, TH17 cells that were preactivated in the presence
(TH17–IL-10
2) or absence (TH17–IL-10
1) of IL-1b were
cocultured with LPS-stimulated monocytes (Fig 4, C). Only
TH17–IL-10
1 cells suppressed IL-1b secretion. This was
dependent on their IL-10 secretion because addition of IL-10–
neutralizing antibodies to the coculture abrogated their ability
to downregulate IL-1b secretion. Exogenous addition of
recombinant IL-10, on the other hand, resulted in reduced
IL-1b secretion, even in coculture with TH17–IL-10
2 cells,
highlighting a role of soluble IL-10 as a potent suppressor of
IL-1b secretion. Interestingly, our control condition with
LPS-stimulated monocytes alone demonstrated that addition of
IL-10–neutralizing antibodies also increases IL-1b secretion in
the absence of T cells, indicating autocrine IL-10 secretion by
monocytes as a negative feedback mechanism for the proinflam-
matory IL-1b production.
Together, these results demonstrate a novel property of
TH17 cells. They can downregulate the inflammatory properties
of antigen-presenting cells, such as monocytes, by reducing
secretion of proinflammatory cytokines, including IL-1b and
TNF-a. In addition, we revealed that TH17 cells differed in their
ability to mediate this anti-inflammatory function depending on
whether they belonged to the IL-101 or IL-102 subset.
TH17 cells from patients with Schnitzler syndrome
have reduced regulatory properties, which are
restored with IL-1b–targeting therapies
Autoinflammatory syndromes comprise a group of rare, mostly
hereditary inflammatory disorders, which present with recurrent
fevers, skin rashes, and arthritis.18 Inflammasome defects lead to
overproduction of IL-1, which mediates immunopathology.
Because we had demonstrated that IL-1b suppressed IL-10
production by TH17 cells,
4 we hypothesized that patients with
autoinflammatory syndromes have reduced regulatory TH17 cell
functions and that IL-1b–blocking therapies, such as IL-1Ra
(anakinra) or anti–IL-1b (canakinumab and gevokizumab),
would restore regulatory properties in TH17 cells. Therefore
autoinflammatory syndromes provide the unique opportunity to
study in an ‘‘experiment of nature’’ human regulatory TH17 cell
functions and their therapeutic perturbations in vivo.
We isolated TH17 cells from healthy age-matched donors, as
well as from patients with Schnitzler syndrome, an autoinflamma-
tory syndrome,19,20 and performed suppression assays with
healthy memory responder T helper cells. Interestingly,
TH17 cells from patients with Schnitzler syndrome showed infe-
rior suppressive functions compared with TH17 cells from healthy
donors in all experiments (Fig 5, A). This correlated with a
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significantly reduced ability of TH17 cells from patients with
Schnitzler syndrome to produce IL-10 upon polyclonal restimula-
tion (Fig 5, B and C). Reduced IL-10 expression levels were not
only restricted to TH17 cells from patients with Schnitzler
syndrome but were also observed in T cells from patients with
systemic juvenile idiopathic arthritis, another autoinflammatory
disease, which is in linewith their increased systemic IL-1b levels
(see Fig E6 in this article’s Online Repository at www.jacionline.
org). IL-17 production was variable and did not show statistical
differences between patients and healthy control donors
(cumulative data not shown).
We next isolated TH17 cells from patients with Schnitzler
syndrome under treatment with IL-1b–blocking drugs. We
hypothesized that therapeutic abrogation of IL-1b signaling in
patients with Schnitzler syndrome would likewise restore
regulatory functions of T helper cell subsets. Indeed, IL-10
expression was restored to baseline levels after treatment with the
IL-1b–neutralizing antibody canakinumabwithin the same patients
after 6 months of treatment (matched pairs). All patients had
systemic inflammation, including recurrent fevers and arthralgias
caused by IL-1b overproduction that subsided on the aforemen-
tioned IL-1b–blocking therapies, resulting in complete remission.10
To further corroborate this finding, we also analyzed IL-10
expression in TH17 cells from patients with Schnitzler syndrome
undergoing treatment with gevokizumab (n 5 2), another IL-1b
mAb, as well as anakinra, an IL-1Ra (n 5 1), which amounts to
a total of 6 patients with this very rare disease. We observed
increased IL-10 expression levels compared with those in patients
who did not receive any IL-1b–targeting treatment (P 5 .05;
Fig 5, C). Although IL-10 expression was significantly
upregulated with gevokizumab and anakinra, it did not amount
to the same high levels seen in patients receiving canakinumab
treatment. Nevertheless, in all of the patients analyzed,
irrespective of the mode of IL-1b blockade, we observed
increased IL-10 expression on IL-1b–blocking treatments
(Fig 5, B and C). In addition, IL-1b–blocking therapy with
canakinumab improved the regulatory properties of TH17 cells
in suppression assays (Fig 5, D). Together, these experiments
demonstrate that patients with Schnitzler syndrome have
TH17 cells with reduced regulatory properties, which can be
restored by IL-1b–blocking therapies.
DISCUSSION
TH17 cells have thus far been considered critical players in
autoimmune tissue inflammation, as well as in pathogen clear-
ance. Recently, GM-CSF, but not IL-17, has been shown to be
the crucial pathogenic TH17 cell cytokine in the EAE mouse
model for multiple sclerosis and to be also associated with human
multiple sclerosis.12,14 This demonstrates that the pathogenicity
of TH17 cells is determined by specific cytokine coexpression
patterns rather than by IL-17 expression alone. This also suggests
that TH17 cells can assume different functions depending on their
cytokine profile. Therefore, TH17 targeting is expected to have
different outcomes depending on whether the downstream
signature cytokine IL-17 or upstream TH17 cell inducers, such
as IL-23 or IL-1b, which determine the heterogeneous cytokine
repertoire of TH17 cells, are blocked. This has important
implications for therapeutic strategies.
We have now demonstrated that TH17 cells, which can
coproduce IL-10, have regulatory functions comparable with
those of Treg cells because of their ability to suppress T helper
cell proliferation. In addition, they have the ability to downregu-
late proinflammatory innate cytokine production by monocytes,
an anti-inflammatory property that Treg cells do not possess.21
However, TH17 cells, which were generated in the presence of
IL-1b, did not have these properties. This demonstrates the exis-
tence of 2 functionally distinct types of TH17 cell subsets, which,
A B
C
FIG 4. TH17 cells suppress IL-1b secretion by monocytes through IL-10 pro-
duction. A, Monocytes were stimulated with LPS for 48 hours and cocul-
tured with TH1, TH2, and TH17 cell subsets that have been isolated
according to the differential expression of CXCR3, CCR4, and CCR6 and pre-
activated for 48 hours with CD3 and CD28 mAbs before coculture for
48 hours. IL-1b was analyzed by using a cytometric bead array. Data
show means 6 SEMs (n 5 3). Numbers indicate P values (paired Student
t test). B, TH1, TH2, and TH17 cell subsets were isolated ex vivo as in
Fig 4, A, and stimulated for 48 hours with plate-bound CD3 and CD28
mAb. IL-10 levels were measured by ELISA after restimulation of equal
numbers of preactivated T cells with phorbol-12-13-dibutyrate and plate-
bound anti-CD3 (1 mg/mL, TR66) for 8 hours. Data show mean 6 SEMs
(n 5 3). C, Monocytes were stimulated as in Fig 4, A, in the presence or
absence of TH17–IL-10
1 or TH17–IL-10
2 cells that had been generated by re-
stimulation of TH17 cells (CCR6
1CCR41CXCR32memory T cells) in the pres-
ence or absence of IL-1b, respectively. IL-10–blocking mAbs (10 mg/ml) or
recombinant IL-10 (10 ng/mL) was added where indicated. Supernatant
was analyzed after 48 hours by cytometric bead array. Data show
mean 6 SEMs (n 5 3).
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 4
NOSTER ET AL 1167
due to differential IL-10 coexpression patterns that can be modu-
lated by IL-1b, possess either proinflammatory or anti-
inflammatory functions. This provides a functional basis for the
previous phenotypic characterization of IL-10–producing human
TH17 cells.
4 Therefore, the view of TH17 cells as major culprits of
autoimmune pathogenesis needs to be refined to take into
consideration a novel functionality with opposite effects.
Having TH17–IL-10
1 cells join the family of Treg helper cell
subsets elicits the question of the differential contribution of
TH17 cells to immunoregulation as compared to other Treg cell
subsets. IL-10 is a regulatory cytokine shared by Treg cells,
TR1 cells, and TH17–IL-10
1 T cells. Although Treg cells are pro-
fessional anti-inflammatory T cells based on several mechanisms
beyond IL-10 production,16,22 TR1 and TH17–IL-10
1 T cells
share coexpression of IL-10 with the proinflammatory cytokines
IFN-g or IL-17, respectively.23 Although the functional signifi-
cance of simultaneous IFN-g and IL-10 coexpression in TR1 cells
has not been clarified, TH17–IL-10
1 cells show a kinetic segrega-
tion of IL-17 and IL-10 expression upon activation at the single-
cell level.4 This allows early proinflammatory IL-17 production
upon antigen recognition, which is followed by IL-10 upregula-
tion as a self-regulatory feedback loop.4 This could potentially
limit bystander tissue inflammation through IL-10–mediated
downregulation of antigen presentation and costimulation by
antigen-presenting cells and, as we have now demonstrated,
proinflammatory cytokine production. Treg cells have been
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FIG 5. Regulatory properties of TH17 cells are abrogated in patients with Schnitzler syndrome but can be
restored upon IL-1b–blocking treatments. A and D, Suppression assays with TH17 cells from healthy donors
and patients with Schnitzler syndrome (SchS) before and after treatment with canakinumab were per-
formed by using allogeneic, healthy, naive, CFSE-labeled responder cells. Numbers in vertical gates indi-
cate percentages of IL-101 or IL-171 cells (small regular font) and percentages of proliferating cells (large
boldface font) among all acquired cells. Dot plot presentation was chosen to simultaneously demonstrate
proliferation by CFSE dilution, as well as cytokine expression of CFSE-unlabeled TH17 cells, which served as
suppressor cells. Data are representative of 3 experiments. B and C, Intracellular cytokine staining and flow
cytometric analysis of TH17 cells from healthy donors, symptomatic patients with Schnitzler syndrome, and
the identical patients (matched pairs) after at least 6months of treatment with canakinumabwith a complete
clinical response. Numbers in gates indicate percentages as in Fig 5, A. Data are representative of 3 exper-
iments (3matched patient pairs before and after treatment; Fig 5, C) or cumulative data (healthy control sub-
jects [n5 6], patients with Schnitzler syndrome without IL-1b–blocking treatment [n5 5], and patients with
Schnitzler syndrome with canakinumab treatment [n 5 3], including additional treatment conditions with
gevokizumab [n 5 2] and anakinra [n 5 1]; Fig 5, B). Error bars indicate mean 6 SEMs. IL-10 expression
was analyzed by using intracellular cytokine staining and FACS analysis of TH17 cells stimulated for 48 hours
with CD3/CD28 mAbs on day 5 of culture, just like patient samples from canakinumab-treated patients.
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reported to acquire the ability to express proinflammatory cyto-
kines in inflammatory microenvironments. This has been inter-
preted as instability or plasticity, including loss of regulatory
activities.24 However, more recent studies have demonstrated
that regulatory functions in Treg cells could be stably maintained
despite IL-17 coexpression.25 This distinguishes IL-101IL-171
Treg cells from IL-101IL-171 TH17 cells on a functional level,
despite similar phenotypes. In addition, we showed that the
anti-inflammatory ability to suppress proinflammatory cytokine
production by innate cells is a property of TH17–IL-10
1 cells
but not Treg cells.21
Overproduction of IL-1b causes considerable inflammation
and tissue damage, as seen in patients with mutations in the
inflammasome who suffer from autoinflammatory syndromes.18
Therefore mechanisms must be in place to curtail inflammasome
activation. While a lot of emphasis has been placed on modes and
mechanisms of inflammasome activation so far, little is known on
how to suppress it. Recently, T cells have been reported to dampen
innate immune responses through inhibition of NLRP1 and
NLRP3 inflammasomes through cell contact–dependent mecha-
nisms.26 We have now demonstrated that a subset of human
TH17 cells, IL-1b–independent TH17 cells (TH17–IL-10
1), can
efficiently suppress innate IL-1b secretion through their ability
to produce IL-10. This shows that human TH17 cells can also limit
innate inflammation. In the future, it will be interesting to dissect
the mechanistic details of how TH17 cells affect distinct compo-
nents of the inflammasome machinery to curtail IL-1b secretion.
We further showed that in the autoinflammatory disorder
Schnitzler syndrome, the ability of TH17 cells to produce IL-10
is reduced. This is consistent with overexuberant inflammasome
activation and thus IL-1b secretion in autoinflammation, which
cannot be sufficiently counterbalanced due to abrogated TH17–
IL-101 cell–mediated feedback mechanisms.
In conclusion, we provide novel insights into the immunoregu-
lation of autoinflammatory syndromes by demonstrating loss of
IL-10 production by TH17 cells, which could be reversed by
therapeutic IL-1b targeting. This could have implications for the
pathogenesis of autoinflammatory and other chronic inflammatory
diseases, as well as for future therapeutic strategies, because
IL-101 and IL-102 TH17 subsets exist with self-regulatory versus
proinflammatory functions, respectively. Therefore the contribution
of TH17 cells to the pathogenesis of different diseases should be as-
sessed considering their existence as 2 functionally distinct subsets.
We thank Dr Anna Simon, internist at the Radboud University Medical
Center in Nijmegen, The Netherlands, for patient recruitment.
Key messages
d This is the first report of functional alterations of human
TH17 cells in patients with autoinflammatory syndromes,
such as Schnitzler syndrome.
d Systemic IL-1b blockage can restore anti-inflammatory
functionalities in human TH17 cells and thus could poten-
tially serve as a therapeutic target inTH17-driven inflamma-
tory diseases, even beyond autoinflammatory syndromes.
d Inautoinflammatory syndromes, suchasSchnitzer syndrome,
overproduction of IL-1b shifts the balance from anti-inflam-
matory to proinflammatory TH17 cell functionalities.
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FIG E1. IL-101 and IL-102 TH17 cells both coexpress proinflammatory GM-CSF and IL-17. A, TH17 cells
were isolated as CXCR32CCR41CCR61 T cells and restimulated in the presence (TH17–IL-10
2) or absence
(TH17–IL-10
1) of IL-1b (10 ng/mL) for 48 hours with plate-bound CD3 and CD28 mAbs. On day 5, intracellular
staining and flow cytometry after phorbol 12-myristate 13-acetate and ionomycin stimulation for 5 hours
was performed. Shown is 1 representative experiment out of 8 experiments. B, Cumulative data (n 5 8,
mean 6 S.E.M). n.s., Not significant (Student t test).
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FIG E2. TH17–IL-10
1 cells can suppress proliferation of distinct T helper cell subsets. TH17 cells were
isolated as CXCR32CCR41CCR61 T cells and restimulated for 48 hours with plate-bound CD3 and CD28
mAbs and expanded for another 3 days, which gave rise to TH17–IL-10
1 cells as shown previously.4
TH17–IL-10
1 cells were then used for suppression assays with naive CD45RA1 CFSE-labeled T helper cells
from the same donors or responder cells isolated as distinct T helper cell subsets according to the indicated
expression of chemokine receptor surface markers. CFSE dilution was assessed on day 4 by FACS.
Representative data shown are from 1 donor for naive, TH1, and TH17 responder cells and from another
donor for TH2 responder cells because cell number limitations from buffy coats limited the simultaneous
analysis of more than 3 different responder cell subsets with TH17–IL-10
1 cells as suppressor cells. Data
are representative of 5 suppression assays with naive, TH1, and TH17 cells as responder cells and 4
experiments for TH2 cells as responder cells. In 2 experiments TH2 cells are defined as CCR4
1CXCR32 cells
and in the other 2 experiments additionally as CCR62 cells. In all experiments TH17–IL-10
1 cells suppressed
proliferation of their respective responder cells, although the degree of suppression varied from experiment
to experiment, as did the degree of the respective control responder cell proliferation in response to OKT3
and feeder cell stimulation in the absence of TH17–IL-10
1 suppressor cells.
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FIG E3. Phenotypic characteristics of Treg cells in suppression assays. Treg
cells were isolated as CD41 T cells by means of MACS separation and FACS
sorted as CD1272 and CD25high. Shown is the representative expression of
forkhead box protein 3 (FoxP3) of this cell population, as determined by
intracellular staining and flow cytometry followed by analysis with FlowJo
software.
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FIG E4. Differential expression of IL-10 by TH17 cells determines their sup-
pressive properties. TH17 cells were isolated as CXCR3
2CCR41CCR61
T cells and restimulated in the presence (TH17–IL-10
2) or absence (TH17–
IL-101) of IL-1b (10 ng/mL) for 48 hours with plate-bound CD3 and CD28
mAbs. TH17–IL-10
2 and TH17–IL-10
1 cells were then used for suppression
assays with naive CFSE-labeled T helper cells from the same donors.
CFSE dilution was assessed on day 4 by FACS (see also Fig 3). Numbers
in quadrants indicate percentages of positive cells, as determined by
intracellular cytokine staining. Data are representative of 6 experiments.
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FIG E5. TH17 cells are potent suppressors of TNF-a secretion by monocytes. A,Monocytes were stimulated
with LPS for 48 hours and cocultured with TH1, TH2, and TH17 cell subsets that have been isolated according
to differential expression of CXCR3, CCR4, and CCR6 and preactivated for 48 hours with CD3 and CD28
mAbs before coculture for 48 hours. Cumulative TNF-a was analyzed by using a cytometric bead array
and ELISA. The same T-cell subsets were stimulated for 48 hours with CD3 and CD28 mAbs in the absence
of monocytes, washed, and analyzed for TNF-a secretion 48 hours later to determine the contribution of
T cell–derived TNF-a levels in the supernatant. Data show mean 6 SEMs (n 5 3). B, Intracellular staining
and flow cytometry of CD141 gated monocytes stimulated as in Fig E5, A, in the presence of brefeldin
A during the culture period. Data are representative of 3 donors.
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FIG E6. IL-10 expression levels in T cells from patients with Still disease (systemic juvenile idiopathic
arthritis). A,Memory T cells were isolated by means of FACS sorting as CD45RA2CD41CCR61CXCR3 T cells
and stimulated with plate-bound CD3 and CD28 mAbs for 48 hours and expanded for another 3 days before
intracellular cytokine staining after phorbol 12-myristate 13-acetate and ionomycin stimulation. Shown are
representative FACS plots for 3 patients with systemic juvenile idiopathic arthritis and 1 patient with
adult-onset Still disease who were not receiving IL-1b–blocking treatments. Numbers in quadrants indicate
percentages of positive cells, as determined by intracellular cytokine staining. B, Cumulative data for
patients with systemic juvenile idiopathic arthritis. Data showmean6 SEMs (n5 3). *P < .03 (Student t test).
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